Elevance Health financials
$392.73−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | $48.89B | $45.44B | $45.11B | $43.89B | $42.58B | $42.65B | $42.85B |
| Gross profit | $13.45B | $14.57B | $11.68B | $12.57B | $13.07B | $13.58B | $11.94B | $12.16B | $13.31B | $12.03B | $11.31B | $12.24B |
| Gross margin | 26.6% | 29.0% | 23.5% | 24.8% | 26.3% | 27.8% | 26.3% | 27.0% | 30.3% | 28.3% | 26.5% | 28.6% |
| Operating income | $2.30B | $2.66B | $581.0M | $1.76B | $2.63B | $3.14B | $946.0M | $1.67B | $3.27B | $3.20B | $1.26B | $1.91B |
| Net income | $1.46B | $1.76B | $547.0M | $1.19B | $1.74B | $2.18B | $418.0M | $1.02B | $2.30B | $2.25B | $856.0M | $1.29B |
| Net margin | 2.9% | 3.5% | 1.1% | 2.3% | 3.5% | 4.5% | 0.9% | 2.3% | 5.2% | 5.3% | 2.0% | 3.0% |
| Diluted EPS | $6.71 | $8.00 | $2.47 | $5.32 | $7.72 | $9.61 | $1.81 | $4.36 | $9.85 | $9.59 | $3.63 | $5.45 |
| EBITDA | $2.67B | $3.02B | $987.0M | $2.14B | $3.01B | $3.51B | $1.34B | $2.00B | $3.60B | $3.54B | $1.26B | $2.34B |
| Operating cash flow | $1.91B | $4.33B | $84.0M | $1.14B | $2.05B | $1.02B | $706.0M | $2.68B | $447.0M | $1.98B | -$2.97B | $2.61B |
| Free cash flow | $1.63B | $4.10B | -$209.0M | $775.0M | $1.79B | $821.0M | $384.0M | $2.35B | $124.0M | $1.70B | -$3.30B | $2.29B |
| Diluted shares | 217.9M | 220.4M | 221.7M | 223.7M | 225.8M | 227.2M | 230.9M | 233.1M | 233.4M | 234.2M | 235.6M | 236.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | $7.50B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $31.04B | $31.84B | $32.05B | $32.10B | $30.19B | $30.00B |
| Total assets | $126.44B | $125.83B | $121.49B | $122.75B | $121.94B | $119.72B |
| Total liabilities | $81.42B | $81.78B | $77.47B | $78.67B | $78.09B | $77.10B |
| Shareholders' equity | $45.02B | $44.04B | $44.03B | $44.08B | $43.85B | $42.62B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology